VANCOUVER, British Columbia, Dec. 31, 2025 (GLOBE NEWSWIRE) -- Hydreight Technologies Inc. (“Hydreight” or the “Company”), a digital health platform enabling on-demand care, pharmacy fulfillment, and enterprise healthcare services across the United States, today announced its entry into the rapidly expanding at-home sexually transmitted infection (“STI”) pre-screening market through an exclusive distribution agreement with Health Screen Collective (“HSC”).
Under the agreement, Hydreight will serve as the exclusive distributor of HSC’s at-home STI pre-screen testing kits across its national platform. The Company has already secured approximately 50,000 pre-orders, with deliveries expected to begin in early 2026.
A Widespread, Under-Diagnosed Public Health Reality
Sexually transmitted infections represent one of the most prevalent and under-diagnosed healthcare challenges in the United States. According to the Centers for Disease Control and Prevention (CDC), approximately one in five people in the U.S. is living with an STI at any given time, with tens of millions of new infections occurring annually. Despite this prevalence, a significant portion of infections remain undiagnosed due to stigma, inconvenience, cost, and long wait times associated with traditional clinic-based testing.
Globally, the World Health Organization (WHO) estimates that more than one million curable STIs are acquired every day, underscoring the scale of the issue and the growing need for accessible, private screening solutions.
Testing in Minutes, Not Days
HSC’s at-home STI pre-screen testing kits are designed to deliver results in minutes rather than days, enabling faster awareness and earlier engagement with care. Using validated lateral-flow immunoassay technology, the kits allow individuals to collect samples privately at home through clear, step-by-step instructions, eliminating the need for clinic visits or laboratory processing delays at the initial screening stage.
Depending on the selected panel, the kits provide pre-screening for multiple common infections, including:
- Chlamydia trachomatis
- Neisseria gonorrhoeae
- Trichomonas vaginalis
- Mycoplasma genitalium
- Candida albicans
- Gardnerella vaginalis
This approach addresses one of the most critical gaps in STI care today: speed matters. Faster screening enables earlier clinical decisions, reduces transmission risk, and improves patient follow-through.
Accuracy & Sensitivity Highlights
According to product validation data and Instructions for Use provided by Health Screen Collective, the at-home STI pre-screen testing kits demonstrate high levels of sensitivity, specificity, and overall accuracy across multiple screened pathogens. The tests utilize validated lateral-flow immunoassay technology and are designed to detect clinically relevant infection markers with performance characteristics comparable to commonly used laboratory-based screening methods for initial detection. These accuracy metrics support the kits’ role as reliable pre-screening tools, enabling faster identification of potential infections and earlier clinical follow-up when integrated into licensed care pathways.
From Pre-Screening to End-to-End Care
The kits are positioned as pre-screening tools, designed to help individuals identify potential infections earlier and take appropriate next steps. When integrated into Hydreight’s platform, users can move seamlessly from pre-screening to licensed medical review, confirmatory testing, clinical consultation, and treatment coordination, where clinically appropriate.
This integrated workflow transforms at-home testing from a standalone product into a connected digital healthcare experience, addressing both access and continuity of care.
Why This Matters for Hydreight
STI screening is a high-frequency, repeat-use healthcare category, driven by public health guidelines and ongoing patient behavior. The combination of recurring screening needs, rapid results, and integrated clinical follow-up aligns directly with Hydreight’s platform-first strategy.
The initial 50,000 pre-orders reflect early demand from enterprise partners, healthcare operators, and distribution channels seeking scalable, at-home pre-screening solutions that can be deployed nationally and embedded into broader digital care workflows.
“This category highlights exactly why our platform exists,” said Shane Madden, Chief Executive Officer of Hydreight. “When you combine fast, at-home screening with licensed providers and national fulfillment, you remove friction from a category that desperately needs it. That’s where real healthcare transformation happens.”
Platform Leverage, Not a One-Off Product
Hydreight views at-home STI pre-screening as another example of how its infrastructure can be leveraged to rapidly launch and scale healthcare services across large, fragmented markets. Rather than operating as a single product, the Company expects this offering to drive repeat engagement, downstream clinical services, pharmacy fulfillment, and long-term platform utilization.
On behalf of the Board of Directors
Shane Madden
Director and Chief Executive Officer
Hydreight Technologies Inc.
Contact
Email: ir@hydreight.com; Telephone: (702) 970-8112
Hydreight Technologies Inc Ranked Number 56 Fastest-Growing Company in North America on the 2024 Deloitte Technology Fast 500™
Hydreight Technologies Recognized as a Top 50 TSX Venture Exchange Company
About Hydreight Technologies Inc.
Hydreight Technologies Inc is building one of the largest mobile clinic networks in the United States. Its proprietary, fully integrated platform has hosted a network of over 3000 nurses, over 300 doctors and a pharmacy network through its Doctor networks across 50 states. The platform includes a built-in, easy-to-use suite of fully integrated tools for accounting, documentation, sales, inventory, booking, and managing patient data, which enables licensed healthcare professionals to provide services directly to patients at home, office or hotel. Hydreight is bridging the gap between provider compliance and patient convenience, empowering nurses, med spa technicians, and other licensed healthcare professionals. The Hydreight platform allows healthcare professionals to deliver services independently, on their own terms, or to add mobile services to existing location-based operations. Hydreight has a 503B pharmacy network servicing all 50 states and is closely affiliated with a U.S. certified e-script and telemedicine provider network.
About VSDHOne - Direct to Consumer Platform
Developed in partnership with Victory Square Technologies (CSE: VST) (OTC: VSQTF) (FWB: 6F6), Hydreight Technologies launched the VSDHOne (Read as VSDH-One) platform. VSDHOne simplifies the entry challenges for companies and medi-spa businesses to enter the online healthcare space compliantly. This platform will help all businesses to launch a direct-to-consumer healthcare brand in a matter of days in all 50 states. Compliant offerings include: GLP-1s, peptides, personalized healthcare treatments, sermorelin, testosterone replacement therapy (“TRT”), hair loss, skincare, sexual health and more. Hydreight invested in technology, legal and infrastructure to launch this platform. The VSDHOne platform offers a complete, and modular end-to-end solution for businesses looking to launch direct-to-consumer healthcare brands. From compliance and telemedicine technology to nationwide doctor and pharmacy networks, VSDHOne provides all the tools needed for a seamless entry into the online healthcare space. The platform is designed to significantly reduce the time and costs associated with launching such services, making it possible for businesses to go live in days instead of months.
Neither TSXV nor its Regulation Services Provider (as that term is defined in policies of the TSXV) accepts responsibility for the adequacy or accuracy of this release. This press release does not constitute an offer of securities for sale in the United States. The securities being offered have not been, nor will they be, registered under the United States Securities Act of 1933, as amended, and such securities may not be offered or sold within the United States absent U.S. registration or an applicable exemption from U.S. registration requirements.
Cautionary Note Regarding Forward-Looking Information
This press release contains statements which constitute “forward-looking information” within the meaning of applicable securities laws, including statements regarding the plans, intentions, beliefs and current expectations of the Company with respect to future business activities and operating performance. Forward-looking information is often identified by the words “may”, “would”, “could”, “should”, “will”, “intend”, “plan”, “anticipate”, “believe”, “estimate”, “expect” or similar expressions and includes information regarding expectations for the 2025 and 2026 strategic outlook, the Company’s growth, margins, and VSDHOne’s and Hydreight’s anticipated performance and related operational metrics. This also includes information regarding Product Orders, which are defined as follows: Product Orders Placed reflect demand initiated by licensees and partners; Product Orders Fulfilled refer to orders processed by pharmacy partners and prepared for delivery; and Product Orders Delivered refer to orders that have reached the patient. Orders may be cancelled or returned, which can affect the relationship between orders placed, fulfilled, delivered, and recognized revenue. Hydreight uses Product Orders Placed as its primary operational KPI because it reflects real-time platform activity and partner demand. All operational and accounting measures reconcile at period end.
Investors are cautioned that forward-looking information is not based on historical facts but instead reflects the Company’s management’s expectations, estimates or projections concerning future results or events based on the opinions, assumptions and estimates of management considered reasonable at the date the statements are made. Although the Company believes that the expectations reflected in such forward-looking information are reasonable, such information involves risks and uncertainties, and undue reliance should not be placed on such information, as unknown or unpredictable factors could have material adverse effects on future results, performance or achievements of the Company. Among the key factors that could cause actual results to differ materially from those projected in the forward-looking information are the following: the ability to obtain requisite regulatory and other approvals with respect to the business operated by the Company and/or the potential impact of the listing of the Company’s shares on the TSXV on relationships, including with regulatory bodies, employees, suppliers, customers and competitors; changes in general economic, business and political conditions, including changes in the financial markets; changes in applicable laws; compliance with extensive government regulation; and the diversion of management time as a result of being a publicly listed entity. This forward-looking information may be affected by risks and uncertainties in the business of the Company and market conditions.
Should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward-looking information prove incorrect, actual results may vary materially from those described herein as intended, planned, anticipated, believed, estimated or expected. Although the Company has attempted to identify important risks, uncertainties and factors which could cause actual results to differ materially, there may be others that cause results not to be as anticipated, estimated or intended. The Company does not intend, and does not assume any obligation, to update this forward-looking information except as otherwise required by applicable law.
Regulatory Statements
Neither the TSX Venture Exchange nor its Regulation Services Provider (as defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this communication. This communication does not constitute an offer to sell, or a solicitation of an offer to buy, securities in the United States. The securities referenced herein have not been and will not be registered under the United States Securities Act of 1933, as amended, and may not be offered or sold in the United States absent registration or an applicable exemption.
